ArticlesSensitization of the Mesoaccumbens Dopamine Response to Nicotine
Section snippets
The role of central nicotinic receptors
Nicotine exerts its effects in the brain by stimulating neuronal nicotinic receptors [55]. The mesoaccumbens DA responses to nicotine are mediated by these receptors because both the acute and sensitized responses to the drug are attenuated by systemic injections of the nicotinic antagonist, mecamylamine, which crosses the blood–brain barrier, but not by the quaternary antagonist, hexamethonium, which penetrates less readily into the brain 11, 30. This conclusion is supported by results that
Regional specificity of the response to nicotine
Electrophysiological studies suggest that the DA neurons that innervate the nucleus accumbens are more sensitive to nicotine that those that innervate the caudate/putamen [35]. Dialysis studies also suggest that nicotine exerts a greater effect on DA overflow in the accumbens than the caudate/putamen [30], and that the projections to the accumbens respond to lower doses of nicotine than those that are required to stimulate the neurons that innervate the caudate/putamen [10]. The expression of
The mechanisms underlying the development of sensitized mesoaccumbens dopamine responses to nicotine
The studies outlined in the sections above imply that systemic nicotine exerts its effects on mesoaccumbens DA neurons by stimulating nicotinic receptors located on the somatodendritic membranes of the cells. Therefore, to test the hypothesis that pretreatment with the drug caused sensitization of the responses mediated by these receptors, the effects of intra-VTA injections of nicotine on DA overflow in the nucleus accumbens were examined. The results of these experiments showed that
Studies with nomifensine
Much of the DA released from nerve terminals in the brain is thought to be cleared from the synaptic cleft by rapid reuptake into the nerve terminal cytoplasm by transporters located within the terminal membrane. The probes used to investigate the effects of drugs on neurotransmitter release are located in the interstitial space between cells. Thus, they do not measure neurotransmitter release directly into the synaptic cleft but overflow into the extracellular space sampled by the probe. A
Electrophysiological correlates of sensitization
The data clearly suggest that the expression of sensitized mesoaccumbens DA responses to nicotine involve the co-stimulation of NMDA receptors. Glutamate-secreting pathways are thought to innervate both the nucleus accumbens and the VTA, and it is possible, therefore, that increased glutamate secretion could influence DA release at the level of the nerve terminals or the electrophysiological responses to nicotine elicited by its effects on DA-secreting cells in the VTA. This issue remains to be
Putative psychopharmacological significance of sensitized dopamine responses to nicotine
Clarke and colleagues [19]have reported that the locomotor stimulant properties of nicotine are abolished if the mesoaccumbens DA system is lesioned by injecting 6-hydroxydopamine bilaterally into the nucleus accumbens. These and other observations led Clarke [16]to suggest that the locomotor stimulant properties of the drug are mediated by its stimulatory effects on the DA projections to the accumbens. This conclusion is consistent with the results of subsequent studies that have both
Acknowledgements
The studies in the author’s laboratory were supported by project grants from the VERUM Foundation and the Wellcome Trust. M. A.-A. was supported by a studentship from the British Pharmacological Society. The raclopride uesed in the studies was a generous gift from Astra Pharmaceuticals Ltd.
References (56)
- et al.
Intercellular communication in the brainWiring vs. volume transmission
Neuroscience
(1995) - et al.
Pharmacology of nicotine and its therapeutic use in smoking cessation and neurodegenerative disorders
Pharmacol. Ther.
(1996) - et al.
Regional variation in the effects of nicotine on catecholamine overflow in the rat brain
Eur. J. Pharmacol.
(1997) Dopaminergic mechanisms in the locomotor stimulant effects of nicotine
Biochem. Pharmacol.
(1990)- et al.
Autoradiographical evidence for nicotinic receptors on nigrostriatal and mesolimbic dopaminergic neurones
Brain Res.
(1985) - et al.
Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area
Brain Res.
(1994) In vivo brain dialysis of neurotransmitters
Trends Pharmacol. Sci.
(1990)Nonlinear relationship between impulse flow and dopamine released by rats midbrain dopaminergic neurons as studied by in vivo electrochemistry
Neuroscience
(1988)- et al.
Specificity in the projection patterns of accumbal core and shell in the rat
Neuroscience
(1991) Neurotransmitter regulation of dopamine neurones in the ventral tegmental area
Brain Res. Rev.
(1993)
Blockade of ‘reverse tolerance’ to cocaine and amphetamine by MK-801
Life Sci.
Amphetamine behavioral sensitization and the excitatory amino acids
Brain Res.
Preferential stimulation of ventral tegmental area dopaminergic neurones by nicotine
Eur. J. Pharmacol.
Role of the locus coeruleus in the noradrenergic response to a systemic administration of nicotine
Neuropharmacology
Regionally specific effects of acute and chronic nicotine on rates of catecholamine and 5-hydroxytryptamine synthesis in rat brain
Eur. J. Pharmacol.
Locomotion induced by ventral tegmental microinjections of nicotinic agonist
Pharmacol. Biochem. Behav.
Microinjections of a nicotinic agonist into dopamine terminal fieldsEffects on locomotion
Pharmacol. Biochem. Behav.
The neural basis of drug cravingAn incentive-sensitization theory of addiction
Brain Res. Rev.
The neurobiology of nicotine addiction
Trends Pharmacol. Sci.
Injections of 6-hydroxydopamine into the ventral tegmental area destroy mesolimbic dopamine neurones but spare the locomotor activating effects of nicotine in the rat
Neurosci. Lett.
Wiring and volume transmission in the central nervous systemthe concept of closed and open synapses
Prog. Neurobiol.
The biological, social and clinical aspects of drug addictionCommentary and debate
Psychopharmacology (Berlin)
MK-801 inhibition of nicotinic acetylcholine receptor channels
Synapse
Characterization of [3H] ABT-418A novel cholinergic channel ligand
J. Pharmacol. Exp. Ther.
Studies on the role of mesolimbic dopamine in the behavioural responses to chronic nicotine
Nicotine binding to brain tissue from drug naive and nicotine-treated rats
J. Pharm. Pharmacol.
The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity
Br. J. Pharmacol.
The effect of ABT-418 on mesolimbic dopamine systems and locomotion in the rat
Br. J. Pharmacol.
Cited by (156)
Herbal biomolecules acting on central nervous system
2022, Herbal Biomolecules in Healthcare Applications5-HT<inf>2A</inf> and 5-HT<inf>2C</inf> receptors as potential targets for the treatment of nicotine use and dependence
2021, Progress in Brain ResearchMenthol facilitates dopamine-releasing effect of nicotine in rat nucleus accumbens
2018, Pharmacology Biochemistry and BehaviorSpecialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders
2016, Brain Research BulletinCitation Excerpt :Similar to other drugs of abuse, nicotine activates the mesolimbic pathway by increasing cell firing of dopaminergic neurons in the VTA via nicotinic receptors (McGehee et al., 1995). Nicotine microinfusions into the VTA which resulted in sensitization of dopamine release (Balfour et al., 1998), also reduced NFL (by 34%, p < 0.05), NFM (by 42%, p < 0.01), and NFH levels (by 38%, p < 0.05) in the VTA but not in the substantia nigra in rats (Bunnemann et al., 2000; Sbarbati et al., 2002) without altering neuron numbers. The similar reductions of NF proteins in the VTA by the chronic treatment of different drugs of abuse with reinforcing properties suggest that common mechanisms underlie these addictive states.